Carbinoxamine Maleate
6 NDCs across 5 manufacturers|4 Generic,2 Brand
Carbinoxamine Maleate is used to treat angioedema, allergic conjunctivitis, rhinitis, allergic, perennial and vasomotor rhinitis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Mar 19, 2003. FDA's Orange Book lists 2 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $1 million on Carbinoxamine Maleate across 5,215 claims for 2,253 beneficiaries.
Carbinoxamine Maleate is available as 6 NDCs from 5 manufacturers (4 generic, 2 brand), with NADAC prices from $0.40 to $7.74 per EA — the most expensive product costs about 19× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
4G / 2B
Manufacturers
5
competing in market
Price Spread
$0.40 – $7.74
per EA, 3 of 6 NDCs
7d Activity
avg -1.5% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Genus Lifesciences Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Histamine-1 Receptor Antagonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
5 manufacturers producing CARBINOXAMINE MALEATE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
RYVENT 6 MG TABLET | $7.7398 per EA | — |
KARBINAL ER 4 MG/5 ML SUSP | $1.1922 per ML | -0.04% |
CARBINOXAMINE ER 4 MG/5 ML SUSP | $1.0469 per ML | -0.03% |
CARBINOXAMINE 4 MG/5 ML LIQUID | $0.9565 per ML | — |
CARBINOXAMINE MALEATE 4 MG TAB | $0.3981 per EA | -2.91% |
CARBINOXAMINE MALEATE 4 MG TAB | $0.3981 per EA | -2.91% |
Frequently Asked Questions
What is Carbinoxamine Maleate used to treat?
Carbinoxamine Maleate is used to treat angioedema, allergic conjunctivitis, rhinitis, allergic, perennial and vasomotor rhinitis, per the National Library of Medicine's MED-RT classification.
When did Carbinoxamine Maleate become available as a generic?
FDA approved the first generic Carbinoxamine Maleate (ANDA) on Mar 19, 2003. The Orange Book currently lists 2 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Carbinoxamine Maleate?
In 2024, Medicare Part D spent $1 million on Carbinoxamine Maleate across 5,215 claims for 2,253 beneficiaries.
How many Carbinoxamine Maleate products are on the market?
The Carbinoxamine Maleate drug market contains 6 NDCs from 5 manufacturers — 4 generic and 2 brand products.
What is the price range for Carbinoxamine Maleate?
NADAC reference prices for Carbinoxamine Maleate range from $0.3981 to $7.7398 per EA — the most expensive product costs about 19× the cheapest. 3 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Carbinoxamine Maleate cheaper than brand?
The average generic NADAC for Carbinoxamine Maleate is $0.3981 per EA, versus $7.7398 for brand-labeled products — brand versions average about 19× the generic price.
Which manufacturers make Carbinoxamine Maleate?
5 manufacturers list Carbinoxamine Maleate in NADAC. Ranked by number of NDCs, the largest are Genus Lifesciences Inc. (2), CarWin Pharmaceutical Associates LLC (1), Aytu Therapeutics, LLC (1), Neos Therapeutics Brands, LLC (1), BioComp Pharma Inc. (1).
How has the price of Carbinoxamine Maleate changed recently?
Over the past 7 days, 0 Carbinoxamine Maleate NDCs rose and 4 fell, with a market-wide average change of -1.5%.